Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Intimation for Consideration Of Unaudited Financial Results For The Quarter Ended June 30, 2019
Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/07/2019 ,inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2019. Aspira Pathlab & Diagnostics Ltd - 540788 - Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Mamta MavDesignation :- Company Secretary and Compliance Officer Aspira Pathlab & Diagnostics Ltd - 540788 - Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Mamta MavDesignation :- Company Secretary and Compliance Officer Aspira Pathlab & Diagnostics Ltd - 540788 - Closure of Trading Window
The financial results of the Company for the quarter ending June 30, 2019 will be declared in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We write to inform you that in view of the foregoing and in accordance with the Code of Conduct for prevention of Insider trading framed by the Company, the Trading Window for Designated Persons will be closed for the period from July 01, 2019 till 48 hours after the declaration of financial results to Stock Exchange. Aspira Pathlab & Diagnostics Ltd - 540788 - Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligation & Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2019
Pursuant to Regulation 23(9) of Securities and Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby submit the disclosure on Related Party Transactions, on standalone basis, drawn in accordance with applicable accounting standards for the half-year ended March 31, 2019. Aspira Pathlab & Diagnostics Ltd - 540788 - Appointment Of Chairman
Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015, We would like to inform that the due to resignation of Mr. Avinash Mahajan from the designation of chairman of the Company w.e.f May 18, 2019 due to personal reason. The Board has appointed Dr. Haseeb Drabu as chairman of the Company w.e.f May 18, 2019. Brief Profie of Dr. Haseeb Drabu : Haseeb A Drabu is professional economist with a diverse skill set and wide-ranging experience. Involved with national economic policy making in India for seven years at the highest level, including in the Planning Commission, Finance Commission and the Economic Advisory Council of the Prime Minister Leveraging the national level experience, worked as the Economic Advisor, the principal economic policy maker at the state level for seven years. Chose to put policy into operations and headed a bank as Chairman and Chief executive for five years. Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement under Regulation 30 (LODR)-Resignation of Chairman
Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015, We would like to inform that the due to resignation of Mr. Avinash Mahajan from the designation of chairman of the Company w.e.f May 18, 2019 due to personal reason. The Board has appointed Dr. Haseeb Drabu as chairman of the Company w.e.f May 18, 2019. Aspira Pathlab & Diagnostics Ltd - 540788 - Appointment Of Chief Financial Officer
Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015, We would like to inform that the Company has appointed Mr. Prahlad Bhanushali as Chief Financial Officer (CFO) and Whole Time Key Managerial Personnel of the Company in terms of Section 203(iii) of Companies Act, 2013 w.e.f. May 19, 2019 at its Board meeting held on Saturday, May 18, 2019. Aspira Pathlab & Diagnostics Ltd - 540788 - Re-Appointment Of Managing Director
Pursuant to Regulation 30 of the Listing (Obligations & Disclosure Requirements) Regulations, 2015, this is to inform that, the Board of Directors in its meeting held on May 18, 2019 (on the recommendation of the Nomination and Remuneration Committee), approved the re-appointment of Dr. Pankaj Shah as Managing Director of the Company for a period of 3 years commencing from August 01, 2019 to July 31, 2022 subject to approval of the members in the ensuing general meeting. The existing term of appointment of Dr. Shah expires on July 31, 2019.